Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GERON CORPGERN · Entity 4989 | Director | January 13, 2023 | January 18, 2023 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 16, 2022 | September 21, 2022 |
| Personalis, Inc.PSNL · Entity 4572 | Director | May 12, 2026 | June 11, 2026 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GERON CORP
Report date January 13, 2023 · Filed January 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,047 |
Reported balance
After 2023-01-13 transaction · row 1
1 source rowRow 1 · 2023-01-13 · Exercise / conversion · Acquired 35,000 · Balance 109,047 |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2023-05-22 | Direct | 0 |
Reported balance
After 2023-01-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-13 · Exercise / conversion · Disposed 35,000 · Balance 0 F1: The options were fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were fully vested.
NEKTAR THERAPEUTICS
Report date September 16, 2022 · Filed September 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,233 |
Reported balance
After 2022-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-09-16 · Grant · Acquired 10,200 · Balance 23,233 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 16, 2022. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.47 · Expires 2030-09-15 | Direct | 20,400 |
Reported balance
After 2022-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-09-16 · Grant · Acquired 20,400 · Balance 20,400 F3: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 16, 2022.
F3: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022.
Personalis, Inc.
Report date May 12, 2026 · Filed June 11, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,756 |
Reported balance
After 2026-05-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 6,250 · Balance 19,756 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control. F2: This amendment corrects the number of shares of Common Stock reported as beneficially owned by the Reporting Person on the Form 4 filed on May 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control.
F2: This amendment corrects the number of shares of Common Stock reported as beneficially owned by the Reporting Person on the Form 4 filed on May 14, 2026.
VERACYTE, INC.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,097 |
Ending reported balance
After 2026-06-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-18 · Sale · Disposed 3,200 · Balance 15,626 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F2: Represents weighted average sales price. Sale prices for the transactions range from $52.26 to $53.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Row 2 · 2026-06-18 · Sale · Disposed 529 · Balance 15,097 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F3: Represents weighted average sales price. Sale prices for the transactions range from $53.29 to $53.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025.
F2: Represents weighted average sales price. Sale prices for the transactions range from $52.26 to $53.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
F3: Represents weighted average sales price. Sale prices for the transactions range from $53.29 to $53.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ILLUMINA, INC.
Report date January 22, 2014 · Filed May 29, 2019
Section 16 reporting ended · disclosed 2019-05-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,249 |
Reported balance
After 2014-01-22 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2014-01-22 · Gift · Disposed 200 · Balance 10,249 |
| Common StockSEC Table I · non-derivative | Direct | 10,049 |
Reported balance
After 2019-05-23 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2019-05-23 · Tax withholding · Disposed 589 · Balance 10,049 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:30 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 529 | $53.55 | $28,328.16 |
DisclosureSEC source: 0001231845-26-000006 · wk-form4_1782160251.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,097 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $53.29 to $53.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:30 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,200 | $52.78 | $168,906.24 |
DisclosureSEC source: 0001231845-26-000006 · wk-form4_1782160251.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,626 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $52.26 to $53.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:56 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 5,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001231845-26-000004 · wk-form4_1781556974.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,826 F1 · kind: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:09 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001231845-26-000001 · form4-05142026_090542.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2036-05-12 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:09 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001231845-26-000001 · form4-05142026_090542.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,366 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control. Read SEC document |
| May 12, 2026 Filed Jun 11, 2026 20:30 UTC Amendment | Personalis, Inc. PSNL · Entity 4572 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001231845-26-000002 · form4a-06112026_040611.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,756 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control. F2 · balance_after: This amendment corrects the number of shares of Common Stock reported as beneficially owned by the Reporting Person on the Form 4 filed on May 14, 2026. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001231845-25-000007 · wk-form4_1765229667.xml · derivative · entry 7 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001231845-25-000007 · wk-form4_1765229667.xml · derivative · entry 6 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 800 | $46.59 | $37,271.84 |
DisclosureSEC source: 0001231845-25-000007 · wk-form4_1765229667.xml · nonDerivative · entry 5 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,554 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $46.32 to $46.98. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 12,808 | $45.84 | $587,080.30 |
DisclosureSEC source: 0001231845-25-000007 · wk-form4_1765229667.xml · nonDerivative · entry 4 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,354 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $45.28 to $46.27. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 6,392 | $44.52 | $284,571.20 |
DisclosureSEC source: 0001231845-25-000007 · wk-form4_1765229667.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,162 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $44.22 to $44.91. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $7.60 | $76,000.00 |
DisclosureSEC source: 0001231845-25-000007 · wk-form4_1765229667.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $7.94 | $79,400.00 |
DisclosureSEC source: 0001231845-25-000007 · wk-form4_1765229667.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 9,674 | $40.02 | $387,191.21 |
DisclosureSEC source: 0001231845-25-000005 · wk-form4_1762549815.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,554 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $40.00 to $40.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 9,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000099 · wk-form4_1750709431.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,228 F1 · kind: Restricted stock units awarded on June 18, 2025 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:21 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,590 | $26.66 | $122,387.76 |
DisclosureSEC source: 0001384101-25-000080 · wk-form4_1750191666.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,907 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $26.39 to $26.92. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:14 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001415889-25-013797 · form4-05202025_080545.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a Change in Control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001384101-25-000002 · wk-form4_1736201774.xml · derivative · entry 4 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,691 | $40.50 | $189,995.82 |
DisclosureSEC source: 0001384101-25-000002 · wk-form4_1736201774.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,497 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $40.37 to $40.78. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,309 | $40.12 | $213,009.82 |
DisclosureSEC source: 0001384101-25-000002 · wk-form4_1736201774.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,188 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $39.46 to $40.36. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $5.28 | $52,800.00 |
DisclosureSEC source: 0001384101-25-000002 · wk-form4_1736201774.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 21:36 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 10,125 | $38.76 | $392,404.50 |
DisclosureSEC source: 0001384101-24-000168 · wk-form4_1732224966.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,497 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F4 · balance_after: Represents weighted average sales price. Sale prices for the transactions range from $38.35 to $39.15. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 21:36 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,006 | $37.77 | $113,537.82 |
DisclosureSEC source: 0001384101-24-000168 · wk-form4_1732224966.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,622 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F3 · balance_after: Represents weighted average sales price. Sale prices for the transactions range from $37.30 to $38.29. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 21:36 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,600 | $36.77 | $58,826.08 |
DisclosureSEC source: 0001384101-24-000168 · wk-form4_1732224966.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,628 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F2 · balance_after: Represents weighted average sales price. Sale prices for the transactions range from $36.26 to $37.15. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 22:25 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 7,500 | $25.00 | $187,500.00 |
DisclosureSEC source: 0001384101-24-000111 · wk-form4_1721341539.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,228 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 8, 2024. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 11,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-24-000100 · wk-form4_1718657288.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,728 F1 · kind: Restricted stock units awarded on June 13, 2024 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:24 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,870 | $20.59 | $79,683.30 |
DisclosureSEC source: 0001384101-24-000091 · wk-form4_1718310242.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,255 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 8, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:21 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001384101-24-000085 · wk-form4_1718137309.xml · derivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 8, 2024. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:21 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,500 | $20.97 | $52,425.00 |
DisclosureSEC source: 0001384101-24-000085 · wk-form4_1718137309.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,125 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 8, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:21 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 2,500 | $10.41 | $26,025.00 |
DisclosureSEC source: 0001384101-24-000085 · wk-form4_1718137309.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 8, 2024. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:21 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001415889-24-014044 · form4-05222024_010557.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-05-17 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a Change in Control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such Change in Control. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:17 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $13.19 Strike: $13.19 | $131,900.00 |
DisclosureSEC source: 0001384101-24-000047 · wk-form4_1712089048.xml · derivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 18, 2022. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:17 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 10,000 | $21.65 | $216,528.00 |
DisclosureSEC source: 0001384101-24-000047 · wk-form4_1712089048.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,125 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 18, 2022. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $21.45 to $22.09. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:17 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $13.19 | $131,900.00 |
DisclosureSEC source: 0001384101-24-000047 · wk-form4_1712089048.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 18, 2022. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 9,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-23-000125 · wf-form4_168669131809605.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,125 F1 · kind: Restricted stock units awarded on June 9, 2023 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:37 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-23-031238 · doc4.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a Change in Control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such Change in Control. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $12.12 | $0.00 |
DisclosureSEC source: 0001384101-23-000042 · wf-form4_167908546405906.xml · derivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires 2023-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 18, 2022. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 18,750 | $22.78 | $427,044.38 |
DisclosureSEC source: 0001384101-23-000042 · wf-form4_167908546405906.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,451 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 18, 2022. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $22.39 to $23.25. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 18,750 | $12.12 | $227,250.00 |
DisclosureSEC source: 0001384101-23-000042 · wf-form4_167908546405906.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 18, 2022. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.12 | $0.00 |
DisclosureSEC source: 0001384101-23-000020 · wf-form4_167779175513694.xml · derivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 10,000 shares Expires 2023-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 18, 2022. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 10,000 | $25.00 | $250,001.00 |
DisclosureSEC source: 0001384101-23-000020 · wf-form4_167779175513694.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,451 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 18, 2022. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.00 to $25.02. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $12.12 | $121,200.00 |
DisclosureSEC source: 0001384101-23-000020 · wf-form4_167779175513694.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 18, 2022. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 00:01 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionStock Options (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001062993-23-001007 · form4.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The options were fully vested. F1 · derivative.exercise_date: The options were fully vested. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 00:01 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 35,000 | $1.10 | $38,500.00 |
DisclosureSEC source: 0001062993-23-001007 · form4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2022 Filed Sep 21, 2022 00:47 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,400 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001209191-22-050814 · doc4.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2030-09-15 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022. Read SEC document |
| September 16, 2022 Filed Sep 21, 2022 00:47 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050814 · doc4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,233 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests in full, one year following September 16, 2022. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 22:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 21,267 | $3.61 | $76,773.87 |
DisclosureSEC source: 0001209191-22-049960 · doc4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,033 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.56 to $3.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 00:12 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 14,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000097 · wf-form4_165542474197562.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,451 F1 · kind: Restricted stock units awarded on June 16, 2022 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| May 17, 2022 Filed May 19, 2022 23:38 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 15,035 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001209191-22-030771 · doc4.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,035 Underlying: Common Stock · 15,035 shares Expires 2032-05-17 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control. Read SEC document |
| May 17, 2022 Filed May 19, 2022 23:38 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantCommon Stock | 10,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-030771 · doc4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,506 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.